



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

July 31, 2020

Corporate Relationship Department,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001.

Through: BSE Listing Centre

Scrip Code: 540 788

Sub: Disclosure under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Advisory vide Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015 read with SEBI Advisory vide Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020, we hereby submit an update by the Company giving brief details of the Material Impact of COVID-19 pandemic on the business of the Company as an Annexure I.

We request you to disseminate the above information on your website.

Due to the prevailing situation amid COVID-19, this intimation is being filed under sd/-

Thanking you,

Yours faithfully,

For Aspira Pathlab & Diagnostics Limited

Sd/-

Mamta Mav

Company Secretary

Contact No. 7208042227

Encl: As above.



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road,
Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

ANNEXURE I

COVID-19 Pandemic and related developments - Update

With respect to the captioned subject, we hereby disclose the material impact of COVID-19 pandemic on the business of the Company under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is as follows:

The Indian Council of Medical Research (ICMR) has given permission to our lab for performing rapid antigen test results.

We have also tied up for COVID-19 testing with ICMR approved lab for sending samples for COVID-19 testing.

Due to getting approval for performing rapid antigen test results, we have witnessed growth in our turnover, which we expect to continue in coming months, depending on spread of COVID-19.